Hippo pathway signaling associated with immune cell trafficking in colorectal cancer.

Authors

null

Natsuko Kawanishi

Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA

Natsuko Kawanishi , Joanne Xiu , Hiroyuki Arai , Francesca Battaglin , Priya Jayachandran , Shivani Soni , Jae Ho Lo , Wu Zhang , Pavel Brodskiy , Anthony Frank Shields , John Marshall , Emil Lou , Jim Abraham , W. Michael Korn , Heinz-Josef Lenz

Organizations

Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, Caris Life Sciences, Phoenix, AZ, Chiba Cancer Center, Chiba, Japan, USC Keck School of Medicine, Los Angeles, CA, Norris Comprehensive Cancer Center, University of Southern Carilfornia, Los Angeles, CA, Karmanos Cancer Institute, Wayne State University, Detroit, MI, Georgetown University, Washington, DC, University of Minnesota School of Medicine, Minneapolis, MN, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA

Research Funding

No funding received

Background: Emerging evidence suggests subsets of the Hippo pathway have multiple functions of tumor development and immune response regulation. Increased understanding of the molecular characteristics of its signaling pathways and the impact on immune cell trafficking will be critical to develop colorectal cancer (CRC) therapies. Methods: A total of 13,008 CRC tumors were analyzed at Caris Life Sciences (Phoenix, AZ) with whole transcriptome and whole exome sequencing (NovaSeq). MSI-H/dMMR was tested by NGS (next generation sequencing), immunohistochemistry (IHC), and fragment analysis. Tumor mutational burden (TMB)-High was determined with a 10-mt/MB cutoff. RNA-deconvolution using QuantiSEQ was used to assess immune cell infiltration in the tumor microenvironment. Consensus molecular subtypes (CMS) were developed using RNA expression data. Gene expression was reported as transcripts per million. Z-score totals of 6 core Hippo genes were calculated in groups: MST1+STK3 (G1), LATS1+LATS2 (G2), YAP1+WWTR1 (G3), and all 6 genes together (G4). Tumors with bottom quartile (QL) z-scores were compared with the top quartile (QH) using χ2/Fisher-Exact test and adjusted with the Benjamini-Hochberg method: adjusted p<.05 was considered significant; unadjusted p<.05 trending. Results: Gene expression levels were significantly positively correlated with each other (Spearman rho: 0.30–0.78). Highest expression levels of G1–4 were seen in CMS4 and lowest in CMS3 with significant differences. MSI-H/dMMR were significantly higher in QL than QH in all (G1: 7.4 vs 4.9%, G2: 7.4 vs 4.5, G3: 8.7 vs 4.1, G4: 7.5 vs 4.5). TMB-H prevalence (%) showed inverse relationships with MSI-H significantly in G1–3 (G1: 10.7 vs 7.5, G2: 10.5 vs 7.1, G3: 12.7 vs 6.2) and trending in G4 (11.0 vs 7.0, p =.006). Considering only MSS tumors, TMB-H trended more often in QL than QH in G1, 3, and 4 (3.6–3.7 vs 2.2–2.6). PD-L1 expression by IHC was significantly higher in QH than QL in all (5.3 vs 3.3%) and MSS tumors (2.2 vs 4.2) only in G3. Z-scores of G1–4 were all positively correlated with immune cell infiltrations. Significantly higher fractions of B cells, M2 macrophages, myeloid dendritic cells, NK cells, neutrophils, and CD8+ T cells were seen in QH than QL with a median fold change of 1.39. G1–4 z-scores all positively correlated with the expression of the analyzed immune-related genes. The highest Spearman rho averages were in HAVCR2 (0.54), CD86 (0.54), CD80 (0.53), PD-L2 (0.5), CD274 (0.46), and LAG3 (0.36). Significantly different mutation rates were seen in QH compared to QL in G1 (TP53, KRAS, PIKCA, SMAD2, AMER1), G2 (APC), G3 (PIK3CA, APC), and G4 (TP53, PIK3CA, KRAS). Conclusions: The Hippo pathway correlated with immune cell trafficking suggesting that YAP1/TAZ signaling may play a critical role in the immune responses. These findings may help develop novel therapeutic strategies targeting the Hippo pathway combined with immune therapies in CRC.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Translational Research

DOI

10.1200/JCO.2022.40.4_suppl.156

Abstract #

156

Poster Bd #

K10

Abstract Disclosures

Similar Abstracts

Abstract

2022 ASCO Annual Meeting

Comprehensive characterization of PTPRT expression in colorectal cancer (CRC).

First Author: Francesca Battaglin

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Association of candidate alterations with primary resistance to KRAS G12D targeting in colorectal cancer.

First Author: Khalid Jazieh

First Author: Pooja Mittal

First Author: Parvathi Myer